Should I buy Acadia Pharmaceuticals (ACAD) stock or is it too late?

Acadia Pharmaceuticals · Health Care · price $19

See the full Acadia Pharmaceuticals (ACAD) profile

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: HC Wainwright & Co. — 60% of its targets hit on this sector (329 calls tested). It aims for $33 (+77 %), call made on September 26, 2026, maturing on September 26, 2027 (18 d ago).

The 1 reliable analyst $33+77 %

The 12 other firms $32+72 %

How to read it: the 1 reliable firms are not filtered by optimism — 1 aim above the price, 0 below, hence their $33 median. “The 12 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Acadia Pharmaceuticals

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
Needham	53 %	+28.1 %	17	$35 +88%
UBS	71 %	+16.3 %	7	$23 +24%
Citigroup	57 %	+11.8 %	7	$33 +77%
RBC Capital	50 %	+7.6 %	18	$36 +93%
Cantor Fitzgerald	42 %	+5.5 %	24	$28 +50%
HC Wainwright & Co.	47 %	+3.0 %	19	$33 +77%
JP Morgan	18 %	-5.9 %	11	$34 +83%
Canaccord Genuity	14 %	-17.9 %	7	$36 +93%

In short — Should you invest in Acadia Pharmaceuticals? Is it too late, still worth it? Analysts are fairly positive (69% buy, median target $33, i.e. +77%), and the most reliable on ACAD targets even higher. But it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

69% of analysts rate it a buy (Buy consensus, 13 ratings) — a sign of market conviction.
Median price target $33, i.e. +77% from the current price ($19).
The most reliable firm on ACAD, B of A Securities (100% hit rate, 3 scored calls), targets $30 (call made on June 30, 2026, maturing on June 30, 2027) (+61%) in its most recent call, and $29 (call made on March 25, 2026, maturing on March 25, 2027) (+56%) in the one coming due soonest.

⚠️ Reasons to hesitate

The consensus is not unanimous: of 13 ratings, 4 are neutral.
A 12-month target is not a guaranteed path: the price can fall in the meantime.
No dividend: your return depends only on price appreciation.

The analyst consensus on ACAD

Median target $33 (+77%) · 13 ratings · Buy consensus

Strong Buy00%

Buy969%

Hold431%

Sell00%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Acadia Pharmaceuticals now?

We won't decide for you. The facts: 69% of analysts rate it a buy, median target $33 (+77%), and B of A Securities (most reliable on ACAD, 100%) targets $30. Weigh that against valuation. This is not personalized advice.

Is it too late to invest in Acadia Pharmaceuticals?

Not according to analysts: the median target ($33) is still +77% above the current price ($19) (most reliable on ACAD: B of A Securities, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Acadia Pharmaceuticals still worth investing in?

It depends on the gap between the price ($19) and its estimated value: analysts target $33 on median (+77%), with 69% buys (most reliable on ACAD: B of A Securities, 100%). Cross-check with their real reliability on ACAD and the cautions above. Information, not advice.

What's the main risk in buying ACAD?

The consensus is not unanimous: of 13 ratings, 4 are neutral.

→ Go deeper: the full Acadia Pharmaceuticals profile (consensus, analyst reliability, price target, performance).